Form 4: Nektar Therapeutics CEO Howard W. Robin Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Nektar Therapeutics CEO Howard W. Robin sold 16,650 shares of common stock on May 17, 2024, to cover tax withholding obligations related to vesting RSUs.
Summary
- On May 17, 2024, Howard W. Robin, the President and CEO of Nektar Therapeutics, sold 16,650 shares of the company's common stock.
- The sale was executed to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- The shares were sold at a weighted average price of $1.75, with individual transactions occurring between $1.72 and $1.80.
- Following the transaction, Robin directly owns 863,239 shares of Nektar Therapeutics common stock and indirectly owns 410 shares through a spouse.
Sentiment
Score: 5
Explanation: The document reflects a neutral sentiment as it reports a routine stock sale for tax purposes, which is a common practice.
Industry Context
This is a routine Form 4 filing related to insider stock transactions. It is common for executives to sell shares to cover tax obligations when RSUs vest.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of the stock sale transaction. |
| 05/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.